Last update May 13, 2019


Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Follicle stimulating hormone (FSH) or follitropin is a hormone of the gonadotropin type, which is found normally in the body. It is synthesized and secreted by gonadotroph cells from the anterior part of the pituitary gland.
FSH regulates pubertal maturation. In women, it matures the oocytes of the ovary and stimulates the production of estradiol (estrogen hormone). In men it regulates the production of sperm.

UROFOLLITROPIN is a human follitropin derived from purified human menopausal gonadotropin (HMG). Other follitropins are obtained by recombinant engineering (follitropin alpha, beta and delta) with similar uses and effectiveness (Weiss 2019, Taketani 2010, Baker 2009).
It is used in infertility treatments (including polycystic ovary syndrome) to induce ovulation in anovulatory patients who do not respond to clomiphene and for the development of multiple follicles (ovarian hyperstimulation) in ovulatory patients in assisted reproduction programmes.
Subsequently, human chorionic gonadotropin (hCG) is usually administered to trigger ovulation.
Subcutaneous or intramuscular administration of a daily dose with ovarian ultrasound monitoring, for 7 to 14 days according to evolution.

Since the last update we have not found published data on its excretion in breastmilk.

Its high molecular weight makes its excretion in breastmilk very unlikely.

Due to its proteinaceous nature it is inactivated in the gastrointestinal tract, not being absorbed, (oral bioavailability is practically zero), which impedes transfer to infant plasma from breastmilk, except in premature babies and the immediate neonatal period, when there may be more intestinal permeability.

There is no proof that its estrogenic effects decrease milk production.
-------------------------------------------------- --------


In assisted reproduction treatments (ART) for infertility, two issues must be taken into account:

1. The possible effects of ART on the infant or breastfeeding.
The medication used, in general, does not interfere with breastfeeding and does not affect the infant, who in these cases is usually older than 6 months and even 1 or 2 years old.

2. The possible interference of breastfeeding with ART.
Breastfeeding, especially frequent, could hinder ovulation. This is the main reason why assisted reproduction services recommend suspending breastfeeding before starting treatment which is usually emotionally costly and, often, also from a financial perspective.

To date, there is no published data that proves that breastfeeding is incompatible with assisted reproduction techniques (ART).

See below the information of these related products:


We do not have alternatives for Urofollitropin.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Urofollitropin is also known as

Urofollitropin in other languages or writings:


Urofollitropin belongs to this group or family:


Main tradenames from several countries containing Urofollitropin in its composition:


Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 980 daltons
Tmax 21 ± 9 hours
50 - 70 hours


  1. Weiss NS, Kostova E, Nahuis M, Mol BWJ, van der Veen F, van Wely M. Gonadotrophins for ovulation induction in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019 Jan 16;1:CD010290. Abstract
  2. Angelini. Urofolitropina (Fostipur). Ficha técnica. 2016 Full text (in our servers)
  3. Ferring. Urofollitropin (Bravelle). Drug Summary. 2014 Full text (in our servers)
  4. Taketani Y, Kelly E, Yoshimura Y, Hoshiai H, Irahara M, Mizunuma H, Saito H, Andoh K, Yanaihara T. Recombinant follicle-stimulating hormone (follitropin alfa) versus purified urinary follicle-stimulating hormone in a low-dose step-up regimen to induce ovulation in Japanese women with anti-estrogen-ineffective oligo- or anovulatory infertility: results of a single-blind Phase III study. Reprod Med Biol. 2010 Feb 23;9(2):99-106. Abstract
  5. Baker VL, Fujimoto VY, Kettel LM, Adamson GD, Hoehler F, Jones CE, Soules MR. Clinical efficacy of highly purified urinary FSH versus recombinant FSH in volunteers undergoing controlled ovarian stimulation for in vitro fertilization: a randomized, multicenter, investigator-blind trial. Fertil Steril. 2009 Apr;91(4):1005-11. Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM